- ReiThera has manufactured the HIV vaccine candidate GRAdHIVNE1, now in Phase 1 trials in South Africa and Zimbabwe.
- The study is backed by the Gates Foundation and involves IAVI, the Ragon Institute, and African clinical partners.
ReiThera has announced its role in the launch of a Phase 1 clinical trial for an HIV vaccine candidate, GRAdHIVNE1, now underway in South Africa and Zimbabwe. The trial aims to assess the safety and T cell-mediated immune responses of the vaccine in both healthy participants and individuals living with HIV.
The vaccine was developed using ReiThera’s proprietary GRAd vector platform and manufactured at its GMP facility in Rome. The GRAd platform is based on a replication-deficient Gorilla adenovirus designed to trigger strong CD8+ T cell responses with minimal pre-existing immunity in humans.
The clinical trial, known as IAVI C114, is sponsored by IAVI and involves collaboration with the Ragon Institute of Mass General Brigham, MIT, Harvard, and several African research and clinical centres. It will enrol approximately 120 participants across sites in Harare, Cape Town, and Durban.
“Our contribution to this important trial reflects ReiThera’s ongoing commitment to applying innovative technology and high-standard GMP manufacturing to global health challenges,” said Stefano Colloca, CEO and co-founder of ReiThera.
The initiative is funded by the Gates Foundation and is part of a broader global strategy to develop HIV prevention solutions that are locally relevant and scientifically advanced. The study is being led by Dr Tariro Makadzange, Executive Director and Founder of the Mutala Trust in Zimbabwe.
